Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include...
Easiest 2x I've seen in a very long time. Confidence level of gaining 100% in the near term is close to 100%. I wouldn't get too greedy holding long on this one. If you zoom out, it's eternal death. Get in and get out.
Some drugs address specific illnesses, while others enhance the pharmacokinetic responses of other drugs, which basically means that it assists other drugs. Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN)’s FHAB™ compound does both by causing swelling around tumors which assists in the immune response and catalyzes the effect of other treatments. As is, SONN...
test
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded in 2011 and is headquartered in Princeton, New Jersey.
test
Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded in 2011 and is headquartered in Princeton, New Jersey.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include...
1. Sonnet Bio Spikes 70% In Pre-Market On FDA Covid-19 Plasma Nod
(FDA) has granted an emergency authorization to use blood plasma from recovered Covid-19 patients as a treatment for the disease.
finance.yahoo.com
2. Sonnet BioTherapeutics Receives $10.5 Million from Exercise of Series A Warrants
as part of the previously announced warrant exchange agreement,...
Higher Price rejection after GAP up + Spike
May try to fill the gap down yet again.
If confirmed
PT1 = 3,34
PT2 = 2,76 (For Gap Fill)
Could see even lower
SONN has bagged too many longs above $7's, thats why im expecting every bounce to $6's or above to get sold off,
they just pulled the rug from $6.4 now down to 5.6
strong Resis at 6-6.25 dollar area
